Immix Biopharma (IMMX) had its "market outperform" rating reaffirmed by Citizens Jmp. They now have a $23.00 price target on the stock.
Immix Biopharma (IMMX) had its price target raised by HC Wainwright from $12.00 to $15.00. They now have a "buy" rating on the stock.
Immix Biopharma (IMMX) is now covered by Morgan Stanley. They set an "overweight" rating and a $20.00 price target on the stock.
Immix Biopharma (IMMX) is now covered by Citizens Jmp. They set a "market outperform" rating and a $23.00 price target on the stock.